CTLA-4 (CD152) inhibits T cell function by activating the ubiquitin ligase Itch.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Molecular Immunology

• Publication date

  2010-06-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.molimm.2010.03.017PMID 20417562
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Itch-/- alphabeta and gammadelta T cells independently contribute to autoimmunity in Itchy mice.

  2008cited by this paper
• The tyrosine phosphatase SHP‐2 regulates differentiation and apoptosis of individual primary T lymphocytes

  2007cited by this paper
• Competition and cooperation: Signal transduction by CD28 and CTLA-4

  2006cited by this paper
• Convergence of Itch-induced ubiquitination with MEKK1-JNK signaling in Th2 tolerance and airway inflammation.

  2006cited by this paper
• Negative regulation of the E3 ubiquitin ligase itch via Fyn-mediated tyrosine phosphorylation.

  2006cited by this paper
• CD152 (CTLA-4) Determines the Unequal Resistance of Th1 and Th2 Cells against Activation-induced Cell Death by a Mechanism Requiring PI3 Kinase Function

  2004cited by this paper
• Multiple functions for CD28 and cytotoxic T lymphocyte antigen-4 during different phases of T cell responses: implications for arthritis and autoimmune diseases

  2004cited by this paper
• Calcineurin imposes T cell unresponsiveness through targeted proteolysis of signaling proteins

  2004cited by this paper
• Diversity of Clonal T Cell Proliferation Is Mediated by Differential Expression of CD152 (CTLA-4) on the Cell Surface of Activated Individual T Lymphocytes1

  2003cited by this paper
• Dysregulation of T lymphocyte function in itchy mice: a role for Itch in TH2 differentiation

  2002cited by this paper
• Tyrosine phosphatase SHP-2 binding to CTLA-4: absence of direct YVKM/YFIP motif recognition.

  2000cited by this paper
• Lymphoproliferative disorder in CTLA-4 knockout mice is characterized by CD28-regulated activation of Th2 responses.

  1999cited by this paper
• CTLA-4 Ligation Suppresses CD28-induced NF-κB and AP-1 Activity in Mouse T Cell Blasts*

  1999cited by this paper
• CTLA-4-Mediated inhibition of early events of T cell proliferation.

  1999cited by this paper
• The itchy locus encodes a novel ubiquitin protein ligase that is disrupted in a18H mice

  1998cited by this paper
• Molecular basis of T cell inactivation by CTLA-4.

  1998cited by this paper
• Lymphoproliferation in CTLA-4-deficient mice is mediated by costimulation-dependent activation of CD4+ T cells.

  1997cited by this paper
• The Role of CTLA‐4 in the Regulation and Initiation of T‐Cell Responses

  1996cited by this paper
• Regulation of T Cell Receptor Signaling by Tyrosine Phosphatase SYP Association with CTLA-4

  1996cited by this paper
• CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells

  1996cited by this paper
• Molecular genetic characterization of six recessive viable alleles of the mouse agouti locus.

  1995cited by this paper
• Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4

  1995cited by this paper
• Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4.

  1995cited by this paper

• Post-translational modifications of immune checkpoints: unlocking new potentials in cancer immunotherapy

  2025cites this paper
• Protein post-translational modifications and tumor immunity: A pan-cancer perspective.

  2025cites this paper
• The expression of pruritus‐associated genes in seven skin diseases: Evidence from microarray

  2025cites this paper
• Cancer Resistance to Immunotherapy

  2025cites this paper
• Immune-checkpoint inhibitor resistance in patients with cancer

  2025cites this paper
• Immune checkpoint inhibitor (ICI) therapy in central nervous system cancers: State-of-the-art and future outlook.

  2025cites this paper
• Therapeutic and immunomodulatory potentials of mesenchymal stromal/stem cells and immune checkpoints related molecules

  2024cites this paper
• Strategic advancement of E3 ubiquitin ligase in the management of hepatocellular carcinoma

  2024cites this paper
• Critical role of the gut microbiota in immune responses and cancer immunotherapy

  2024cites this paper
• Induction of FoxP3 Pre-mRNA Alternative Splicing to Enhance the Suppressive Activity of Regulatory T Cells from Amyotrophic Lateral Sclerosis Patients

  2024cites this paper
• Modulation of Suppressive Activity and Proliferation of Human Regulatory T Cells by Splice-Switching Oligonucleotides Targeting FoxP3 Pre-mRNA

  2023cites this paper
• Role of Cys Residues of C-Terminal Sh2 Domain of Phosphoinositide 3-Kinase in its Conformational Stability and Cd28-Binding Ability

  2022cites this paper
• In or out of control: Modulating regulatory T cell homeostasis and function with immune checkpoint pathways

  2022cites this paper
• The role of immune regulatory molecules in rheumatoid arthritis: Implication for etiopathogenesis and prospective for treatment

  2022cites this paper
• Ubiquitination in T-Cell Activation and Checkpoint Inhibition: New Avenues for Targeted Cancer Immunotherapy

  2021cites this paper
• Regulation of Cancer Immune Checkpoints: Molecular and Cellular Mechanisms and Therapy

  2020cites this paper
• Phosphorylation: A Fast Switch For Checkpoint Signaling.

  2020cites this paper
• Itch regulation of innate and adaptive immune responses in mice and humans

  2020cites this paper
• Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance.

  2020cites this paper
• Molecular interactions of the CTLA-4 cytoplasmic region with the phosphoinositide 3-kinase SH2 domains.

  2020cites this paper
• CTLA-4 (CD152): A versatile receptor for immune-based therapy.

  2019cites this paper
• Ubiquitin Ligases in Cancer Immunotherapy - Balancing Antitumor and Autoimmunity.

  2019cites this paper
• Regulation of autoimmune disease by the E3 ubiquitin ligase Itch.

  2019cites this paper
• CTLA-4 Expression Inversely Correlates with Kidney Function and Serum Immunoglobulin Concentration in Patients with Primary Glomerulonephritides

  2019cites this paper
• Immune inhibitory proteins and their pathogenic and therapeutic implications in autoimmunity and autoimmune hepatitis

  2019cites this paper
• CTLA-4 Mediates Inhibitory Function of Mesenchymal Stem/Stromal Cells

  2018cites this paper
• CTLA-4 and PD-1 Control of T-Cell Motility and Migration: Implications for Tumor Immunotherapy

  2018cites this paper
• The Yin and Yang of regulatory T cell and therapy progress in autoimmune disease.

  2017cites this paper
• Interference of the T Cell and Antigen-Presenting Cell Costimulatory Pathway Using CTLA4-Ig (Abatacept) Prevents Staphylococcal Enterotoxin B Pathology

  2017cites this paper
• Regulators of Tfh Cell Differentiation

  2016cites this paper
• Nivolumab and pembrolizumab as immune-modulating monoclonal antibodies targeting the PD-1 receptor to treat melanoma

  2015cites this paper
• EphB4 Promotes Osteogenesis of CTLA4-Modified Bone Marrow-Derived Mesenchymal Stem Cells Through Cross Talk with Wnt Pathway in Xenotransplantation

  2015cites this paper
• Effect of cytotoxic T-lymphocyte-associated protein 4 on CD4(+)CD25(+) regulatory T cells in murine schistosomiasis japonica.

  2014cites this paper
• Personalized treatment of Sézary syndrome by targeting a novel CTLA4:CD28 fusion

  2014cites this paper
• Impact of the CTLA-4/CD28 axis on the processes of joint inflammation in rheumatoid arthritis.

  2013cites this paper
• RNA Interference of CTLA4 in Human Leukaemia T Cells

  2013cites this paper
• CTLA-4 and autoimmunity: new insights into the dual regulator of tolerance.

  2013cites this paper
• Concordance of preclinical and clinical pharmacology and toxicology of therapeutic monoclonal antibodies and fusion proteins: cell surface targets

  2012cites this paper
• Blockade of CTLA-4 Decreases the Generation of Multifunctional Memory CD4+ T Cells In Vivo

  2011cites this paper
• In Vivo + Generation of Multifunctional Memory CD 4 Blockade of CTLA-4 Decreases the Emanual Maverakis

  2011cites this paper
• This information is current as T Cells In Vivo + Generation of Multifunctional Memory CD 4 Blockade of CTLA-4 Decreases the

  2011cites this paper
• Signalling of E3 ubiquitin-protein ligases in the regulation of priming and tolerance of T cells

  2010influential citation